Vermillion, Inc. (NASDAQ:VRML) Files An 8-K Other EventsItem 8.01.Other Events.
Vermillion, Inc. (the “Company”) is filing this Current Report on Form 8-K to amend Exhibit 23.1 (the “Original Exhibit 23”) to the Company’s Annual Report on Form 10-K for the year ended December 31, 2016, filed by the Company with the Securities and Exchange Commission on March 30, 2017 (the “Form 10-K”).In the Original Exhibit 23, the Company’s independent registered public accounting firm, BDO USA, LLP, consented to the incorporation by reference into various of the Company’s registration statements of its report dated March 30, 2017 that is included in the Form 10-K.In the Original Exhibit 23, reference to the Company’s Registration Statement on Form S-3 (File No. 333-189929) was inadvertently omitted. The revised and updated consent attached hereto as Exhibit 23.1 (the “Revised Exhibit 23”) supersedes and replaces the Original Exhibit 23. The Revised Exhibit 23 does not change any previously reported financial results or any other disclosures contained in the Form 10-K.
Item 9.01.Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
Description |
|
23.1 |
Consent of BDO USA, LLP, Independent Registered Public Accounting Firm |
VERMILLION, INC. ExhibitEX-23.1 2 vrml-20171027xex23_1.htm EX-23.1 2017-10-27 8K Ex 231 Exhibit 23.1 Consent of Independent Registered Public Accounting Firm Vermillion,…To view the full exhibit click here
About Vermillion, Inc. (NASDAQ:VRML)
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
